FOLH1 and prostate carcinoma: Upregulation of prostate-specific membrane antigen (PSMA) is present in over 90% of prostate cancer patients [2] and can be an early indicator for the presence of a hormone-sensitive or castrate-resistant prostate cancer phenotype [3].